A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (6) , 1027-1039
- https://doi.org/10.1016/j.clinthera.2007.06.011
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidNeuropharmacology, 2007
- BupropionDrugs of Today, 2006
- Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapyPsychopharmacology, 2005
- Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptorsNature, 2005
- Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenariosTobacco Control, 2005
- Smoking behaviour in Taiwan, 2001Tobacco Control, 2005
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigationPsychopharmacology, 2004
- Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiographyJournal of Neurochemistry, 2002
- Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking CessationDrugs, 2002